Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Q1 2025 value amounting to $15.0 million.

  • Arcturus Therapeutics Holdings' Non-Current Debt changed N/A to $15.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $40.6 million for FY2021, which is 19348.5% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Non-Current Debt stood at $15.0 million for Q1 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Non-Current Debt peaked at $58.1 million during Q1 2021, and registered a low of $15.0 million during Q1 2025.
  • For the 4-year period, Arcturus Therapeutics Holdings' Non-Current Debt averaged around $37.7 million, with its median value being $39.2 million (2022).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Non-Current Debt soared by 28692.44% in 2021 and then tumbled by 3757.41% in 2023.
  • Over the past 4 years, Arcturus Therapeutics Holdings' Non-Current Debt (Quarter) stood at $40.6 million in 2021, then dropped by 21.15% to $32.0 million in 2022, then tumbled by 37.57% to $20.0 million in 2023, then dropped by 25.0% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q1 2025, $20.0 million for Q3 2023, and $32.0 million during Q3 2022.